Cure after surgery for hepato-pancreato-biliary cancers: A systematic review
M Maspero, C Sposito, V Mazzaferro, G Ercolani… - Digestive and Liver …, 2024 - Elsevier
Background Patients undergoing curative-intent surgery for hepato-pancreato-biliary (HPB)
malignancies may achieve statistical cure ie, a mortality risk which aligns with the general …
malignancies may achieve statistical cure ie, a mortality risk which aligns with the general …
A comprehensive review of deep learning approaches for magnetic resonance imaging liver tumor analysis
YS Velichko, N Gennaro… - Advances in …, 2023 - advancesinclinicalradiology.com
Clinical Motivation (Background) Hepatocellular carcinoma (HCC) is the most common type
of liver cancer, accounting for approximately 80% to 90% of cases. It typically develops in …
of liver cancer, accounting for approximately 80% to 90% of cases. It typically develops in …
Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study
Background: Patient-reported outcomes (PRO) measures relevant to domains most
important to patients with HCC who received locoregional therapies are needed to advance …
important to patients with HCC who received locoregional therapies are needed to advance …
[HTML][HTML] Review of practice informing data and current state of NCCN consensus guidelines in hepatobiliary cancers
V Corbett, D Li, A Chauhan - Hepatobiliary Surgery and Nutrition, 2023 - ncbi.nlm.nih.gov
© HepatoBiliary Surgery and Nutrition. All rights reserved. HepatoBiliary Surg Nutr 2023; 12
(5): 798-803| https://dx. doi. org/10.21037/hbsn-23-372 guidelines, are more frequently …
(5): 798-803| https://dx. doi. org/10.21037/hbsn-23-372 guidelines, are more frequently …
[HTML][HTML] Locoregional Therapies for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death
worldwide with an average five-year survival rate in the US of 19.6%. With the advent of HBV …
worldwide with an average five-year survival rate in the US of 19.6%. With the advent of HBV …
Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a reconstructed individual patient data meta-analysis
JX Peng, LZ Wang, QT Wang, HL Li, LJ Lin… - Frontiers in …, 2024 - frontiersin.org
Background: Hepatitis B, often leading to Hepatocellular carcinoma (HCC), poses a major
global health challenge. While Tenofovir (TDF) and Entecavir (ETV) are potent treatments …
global health challenge. While Tenofovir (TDF) and Entecavir (ETV) are potent treatments …
[HTML][HTML] Gene targets with therapeutic potential in hepatocellular carcinoma
S Shodry, YTN Hasan, IR Ahdi… - World Journal of …, 2024 - pmc.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide. Major treatments include liver transplantation, resection, and chemotherapy, but …
worldwide. Major treatments include liver transplantation, resection, and chemotherapy, but …
Long-term survival analysis of ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma conforming to the Milan criteria: primary versus …
J Zhang, G Guo, T Li, C Guo, Y Han… - International Journal of …, 2024 - Taylor & Francis
Background This study compared long-term outcomes between patients with initial
hepatocellular carcinoma (IHCC) and those with recurrent HCC (RHCC) treated with …
hepatocellular carcinoma (IHCC) and those with recurrent HCC (RHCC) treated with …
[HTML][HTML] Imaging-based prediction of hepatocellular carcinoma recurrence after microwave ablation as bridge therapy: A glimpse into the future
C Lindner, R San Martín, A Concha… - World Journal of …, 2024 - pmc.ncbi.nlm.nih.gov
Liver transplantation (LT) remains the treatment of choice for early-stage hepatocellular
carcinoma (HCC) and offers the best long-term oncological outcomes. However, the …
carcinoma (HCC) and offers the best long-term oncological outcomes. However, the …
Detection of γ-OHPdG in circulating tumor cells of patients with hepatocellular carcinoma as a potential prognostic biomarker of recurrence
M Aggarwal, M Kuo, Z Zhu, S Gould, K Zhang… - Gastro Hep …, 2024 - Elsevier
Abstract Background and Aims Blood-based biomarkers for hepatocellular carcinoma (HCC)
and its recurrence is lacking. We previously showed that hepatic γ-hydroxy-1, N 2-propano …
and its recurrence is lacking. We previously showed that hepatic γ-hydroxy-1, N 2-propano …